FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma.
about
A soluble form of the giant cadherin Fat1 is released from pancreatic cancer cells by ADAM10 mediated ectodomain sheddingIntrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapiesMolecular profiling of biliary tract cancer: a target rich diseaseMicroRNA-26a promotes cholangiocarcinoma growth by activating β-cateninUndifferentiated embryonal liver sarcoma in childhood: A case report.Dual processing of FAT1 cadherin protein by human melanoma cells generates distinct protein productsThe Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia.Sleeping giants: emerging roles for the fat cadherins in health and disease.Array comparative genomic hybridization identifies novel potential therapeutic targets in cholangiocarcinoma.HER2/neu-directed therapy for biliary tract cancer.Cholangiocarcinomas can originate from hepatocytes in mice.SALL4 is a novel therapeutic target in intrahepatic cholangiocarcinoma.Oncogenic potential of IDH1R132C mutant in cholangiocarcinoma development in miceFunction and cancer genomics of FAT family genes (review)AKT and ERK1/2 signaling in intrahepatic cholangiocarcinoma.FAT1: a potential target for monoclonal antibody therapy in colon cancer.Reduced expression of P120 catenin in cholangiocarcinoma correlated with tumor clinicopathologic parametersRole of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinomaImmunohistochemical Examination of a Resected Advanced Hilar Cholangiocarcinoma Arising in a 29-Year-Old Male without Primary Sclerosing Cholangitis.Multi-biomarker pattern for tumor identification and prognosis.Molecular factors associated with recurrence and survival following hepatectomy in patients with intrahepatic cholangiocarcinoma: a guide to adjuvant clinical trials.Genomic and transcriptional alterations of cholangiocarcinoma.New Horizons for Precision Medicine in Biliary Tract Cancers.Regulation and function of the atypical cadherin FAT1 in hepatocellular carcinoma.HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?High expression of ErbB2 contributes to cholangiocarcinoma cell invasion and proliferation through AKT/p70S6KFAT1 inhibits cell migration and invasion by affecting cellular mechanical properties in esophageal squamous cell carcinoma.PRKAR1A is overexpressed and represents a possible therapeutic target in human cholangiocarcinoma.
P2860
Q21132301-DAE02942-3101-4C03-88B8-0E2D0FFB67C2Q27002547-76E7AF58-99FB-42EF-ABE6-A3799082DF9EQ28072275-2CDA4B3A-9B90-435E-945F-908AD0277FB9Q28263940-63484BB5-F1AB-4F52-9F5A-997C4959AA18Q33967639-9285CD3A-21A6-4F85-BAFB-52E9D9469280Q34193325-9C48A9D2-A67F-48F0-BBC4-CE9E33D140EDQ34235906-8D4BCE21-1A20-47ED-9C7B-12021C36C267Q34347563-48617495-586F-472B-9889-8984A4136744Q34978321-4D4C5C21-3F90-4531-9E90-FE4CF4D21797Q35748129-D04E2F32-2C10-4FAE-96D7-53D4BCF003B8Q36129118-CC08016A-E105-47CD-856D-7E12CA2B5795Q36413790-0BBB6AFA-ABEF-4696-9072-9CE97327A797Q36501683-BEAD52F5-5605-41B2-892E-4E34B90AE18CQ36642936-4E128CF2-1577-4205-B6A2-918A6B91CA03Q37045823-81EABBB6-743D-4506-BEDC-E2F266B3E5D3Q37061340-AB885DD1-B9C2-4575-8F5E-C113FCC5AF83Q37284831-F42FF2EE-08B3-4C48-BE0B-87711820F61EQ37351498-ADDD6104-0147-44F9-960B-6B706202B7F3Q37784142-FB299E6E-3FFA-4661-A8B8-B9E5996470D5Q37890322-FBB8AEB8-5E94-4EA7-ADC8-6A2D430439F4Q38152291-C974A2D4-7391-473D-895C-97ACAF40D20BQ38188515-4564DE54-9013-4DFA-BE9F-284D5B56CD2CQ38619219-7AE5DF32-61FD-4FE2-A829-DC3CA710C12DQ39018915-45CF94AC-52D3-49C7-9E2C-8231F942DB78Q39040859-AD316FCA-A6F4-46D4-BAFC-357F018DCBBAQ39664471-084A9C05-510E-40D4-91B5-B67E692A6C80Q52642929-B0A7A6BB-3451-402B-8878-5948BD79A190Q54651230-E49FE6F9-8F4F-49E7-8C33-7855C8217542
P2860
FAT, E-cadherin, beta catenin, HER 2/neu, Ki67 immuno-expression, and histological grade in intrahepatic cholangiocarcinoma.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
2005年论文
@zh
2005年论文
@zh-cn
name
FAT, E-cadherin, beta catenin, ...... trahepatic cholangiocarcinoma.
@ast
FAT, E-cadherin, beta catenin, ...... trahepatic cholangiocarcinoma.
@en
type
label
FAT, E-cadherin, beta catenin, ...... trahepatic cholangiocarcinoma.
@ast
FAT, E-cadherin, beta catenin, ...... trahepatic cholangiocarcinoma.
@en
prefLabel
FAT, E-cadherin, beta catenin, ...... trahepatic cholangiocarcinoma.
@ast
FAT, E-cadherin, beta catenin, ...... trahepatic cholangiocarcinoma.
@en
P2093
P2860
P356
P1476
FAT, E-cadherin, beta catenin, ...... trahepatic cholangiocarcinoma.
@en
P2093
A S-Y Leong
J Settakorn
N Kaewpila
P2860
P304
P356
10.1136/JCP.2005.026575
P407
P577
2005-12-01T00:00:00Z